Marmara University Faculty of Medicine

Istanbul 34899

0 studies enrolling now · 3 studies all time

What they study most

HER2+ Metastatic Breast Cancer (MBC), Thyroid Eye Disease

Studies at this site

• An Open-label Study (OLE) for Non-responders of VRDN-001-101 (NCT05176639) and VRDN-001-301 (NCT06021054) — Completed
• An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED) (THRIVE-2) — Completed
• A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting — Completed